. 2015 May 1;4:14. doi: 10.1186/s13756-015-0055-6
© Harris et al.; licensee BioMed Central. 2015
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Figure 2.
30-day mortality for patients treated with BLBLI or carbapenem as definitive monotherapy.